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A randomized-controlled clinical trial evaluating clinical and
radiological outcomes after 3 and 5 years of dental implants
placed in bone regenerated by means of GBR techniques with or
without the addition of BMP-2
Abstract
OBJECTIVE: The aim of this randomized-controlled clinical trial was to evaluate the long-term
outcome of implants placed in bone augmented with a xenogenic bone substitute material and a collagen
membrane with or without the addition of recombinant human bone morphogenetic protein-2
(rhBMP-2). MATERIAL AND METHODS: Eleven patients received a total of 34 implants placed into
sites exhibiting lateral bone defects. In a split mouth design, the defects were randomly treated with the
graft material and the collagen membrane either with (test) or without (control) rhBMP-2. The patients
were examined 3 and 5 years after insertion of the prosthetic restoration. Student's paired t-test was
performed to detect differences between the two groups. RESULTS: The survival rate at 3 and 5 years
was 100% for both groups. The peri-implant soft tissues were stable and healthy without any difference
between the two groups. The prosthetic reevaluation demonstrated four loose prosthetic screws during
the first 3 years and seven ceramic chippings after 3 and 5 years. The mean distance between the first
bone to implant contact to implant abutment junction at 3 years was 1.37 mm (test), 1.22 mm (control),
and 1.38 mm (test), and 1.23 mm (control) at 5 years. The difference of <0.2 mm between test and
control implants was not statistically significant. The mean change of the marginal bone level between
baseline and 5 years ranged from -0.07 mm (mesial, test), -0.11 mm (distal, test), -0.03 mm (mesial,
control), to +0.13 mm (distal, control). No statistically significant differences were observed between
test and control sites. CONCLUSION: Implants placed in bone augmented with and without rhBMP-2
revealed excellent clinical and radiological outcomes after 3 and 5 years.
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Objective: The aim of this randomized controlled clinical trial was to evaluate the long-term 
outcome of implants placed in bone augmented with a xenogenic bone substitute material and 
a collagen membrane with or without the addition of recombinant human bone morphogenetic 
protein-2 (rhBMP-2). 
Material and Methods: Eleven patients received a total of 34 implants placed into sites 
exhibiting lateral bone defects. In a split mouth design the defects were randomly treated with 
the graft material and the collagen membrane either with (test) or without (control) rhBMP-2. 
The patients were examined 3- and 5-years after insertion of the prosthetic restoration. 
Student’s paired t-test was performed to detect differences between the two groups. 
Results: The survival rate at 3 and at 5 years was 100% for both groups. The peri-implant 
soft tissues were stable and healthy without any difference between the two groups. The 
prosthetic reevaluation demonstrated 4 loose prosthetic screws during the first 3 years and 7 
ceramic chippings after 3 and 5 years. The mean distance between the first bone to implant 
contact to implant abutment junction at 3 years was 1.37mm (test), 1.22mm (control), and 
1.38mm (test), and 1.23mm (control) at 5 years. The difference of < 0.2mm between test and 
control implants was not statistically significant. The mean change of the marginal bone level 
between baseline and 5 years ranged from -0.07mm (mesial, test), -0.11mm (distal, test), -
0.03mm (mesial, control), to +0.13mm (distal, control). No statistically significant differences 
were observed between test and control sites. 
Conclusion: Implants placed in bone augmented with and without rhBMP-2 revealed 




Successful endosseous implant insertion in the alveolar ridge requires a sufficient quality and 
quantity of bone at the recipient site. The long-term prognosis of dental implants is adversely 
affected by an inadequate bone volume (Lekholm et al.1986). 
In cases of insufficient quantity of host bone a variety of surgical techniques have been 
described to augment bone prior to or in combination with dental implant placement. Among 
these methods, guided bone regeneration (GBR) is one of the best-documented techniques for 
intraoral bone augmentation (for a review see Hämmerle & Jung 2003). The initial and 
successful use of expanded polytetrafluoroethylene membranes (ePTFE) as barriers has made 
this material the standard for guided bone regeneration (Dahlin et al. 1991; Davarpanah et al. 
1991; Nevins & Mellonig 1992). Nevertheless, this membrane has a number of disadvantages, 
like the necessity for a second surgery to remove the membrane and a high risk for membrane 
exposure (Simion et al.1994; Machtei 2001). Autogenous bone grafts have most frequently 
been used to support GBR membranes and are well documented in the literature (Buser et 
al.1996; Nevins et al. 1998; Von Arx et al. 2001a). However, major shortcomings of the 
autogenous bone grafting are the discomfort for the patient since there are two operation sites 
and the morbidity associated with the harvesting procedure (Nkenke et al. 2004).  
To overcome the described disadvantages of non-resorbable membranes and autogenous bone 
grafting, research has focused on resorbable membranes and the use of biomaterials as bone 
substitute for alveolar bone (Mayfield et al. 1997, Zitzmann et al. 1997). Several animal and 
clinical studies showed gain in marginal bone, using resorbable membranes in combination 
with an underlying, osteoconductive membrane supporting material (Hockers et al. 1999, 
Brunel et al. 2001, Hämmerle & Lang 2001, Zitzmann et al. 2001, Strietzel et al. 2006). On 
the other hand, osteoconductive scaffolds have been combined with osteoinductive proteins to 
further improve bone regeneration. It has been shown that these osteoinductive proteins such 
as bone morphogenetic protein-2 (BMP-2) can trigger the differentiation of mesenchymal 
stem cells and osteoprogenitor cells to become osteoblasts and to enhance the migration of 
dedicated bone forming cells into the defect site (Urist 1965; Campbell & Kaplan 1992; 
Ripamonti & Reddi 1994). A variety of clinical and experimental studies have demonstrated, 
that bone morphogenetic protein can successfully be used in bone regeneration (Boyne et al. 
1997; Howell et al. 1997; Jung et al. 2003; Barboza et al. 2004). A recent clinical and 
histomorphogenetic study showed that the results of GBR procedures in humans could be 
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improved by the addition of recombinant human bone morphogenetic protein-2 (rhBMP-2) 
(Jung et al. 2003). 
The successful use of implants placed in regenerated bone has previously been reported 
(Zitzmann et. al. 2001; Hämmerle et al. 2002). However, the majority of the studies evaluated 
the implants over an observation period of less than 5 years and are mainly prospective or 
retrospective cohort studies (Lorenzoni et al. 1999; Christensen et al. 2003). In addition, very 
scarce data are available on studies evaluating the long-term outcome of implants placed in 
bone regenerated by the use of osteoinductive proteins (Cochran et al. 2000). Hence, there is 
an increased need on studies with a high level of evidence evaluating long-term outcome of 
implants placed in regenerated bone either with the principle of GBR or with the use of 
osteoinductive proteins. 
The aim of the present randomized controlled clinical trial was to evaluate the clinical and 
radiological outcomes of implants placed in bone augmented with a xenogenic bone substitute 
material and a collagen membrane with or without the addition of rhBMP-2 3 and 5 years 
after implant loading.
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MATERIALS AND METHODS 
 
Patients 
In the present randomized, controlled clinical study 11 patients (7 women and 4 men) were 
treated between December 1999 and March 2000 at the University of Zurich (Jung et al. 
2003). The local ethical committee approved all procedures and materials. All patients 
obtained informed consent. The median age of the patients at the time of implant insertion 
was 53 years (range 27 to 75 years) and they were all in good general health.  
A total of 34 implants (Mk III and Mk IV Brånemark, Nobel Biocare, Gothenburg, Sweden) 
were placed into sites exhibiting bony defects. Eighteen implants served as test sites and 16 as 
control sites. For data analysis one test and one control implant from each patient was 
included. If a patient had several implants fulfilling the inclusion criteria, two implants (one 
test, one control) had been randomly chosen for clinical and radiological examination. 
 
Regeneration material 
Recombinant human bone morphogenetic protein (rhBMP-2) was produced in a licensed 
laboratory under good laboratory practice according to a method previously described (Weber 
et al. 2002). The method of loading the rhBMP-2 to the demineralized bovine bone mineral 
(Bio-Oss® spongiosa granules 0.25-1mm, Geistlich AG, Wolhusen, Switzerland) was 
previously described (Jung et al. 2003). The mean dose of rhBMP-2 used for the test sites was 
0.18mg (SD 0.13, range 0.06 to 0.48 mg).  
 
Surgical procedure 
The test and the control sites represented either single tooth gaps or multiple teeth gaps. For 
data analysis one test and one control implant from each patient was included.  
The surgical procedure was performed according to a previously published protocol (Jung et 
al. 2003). In brief, after raising a full thickness mucosa flap the implant site was prepared 
according to standard protocols for the Brånemark System. After implant insertion the type of 
defect (dehiscence or fenestration) and the dimension of the defect were noted for each defect.  
The defect sites were grafted with the demineralized bovine bone mineral with or without 
rhBMP-2. Each grafted site was covered with a bioresorbable collagen membrane (Bio-
Gide, Geistlich AG, Wolhusen, Switzerland). After periosteal releasing incisions the flap 
was repositioned and adapted to allow a submerged implant healing.  
 6 
Reentry and prosthetic procedure 
After an average healing period of 6.0 months (SD 0.17, range 5.7-6.2), a reentry operation 
was performed for abutment connection, to measure the residual defects and to harvest bone 
biopsies. At this time point, all implants were stable (Jung et al. 2003). Six to 8 weeks later, 
impressions were taken at the level of the implant shoulder with screw-retained impression 
copings. Two to four weeks later the prosthetic reconstructions (Table 1) have been inserted 
and periapical radiographs were performed using the parallel technique. These x-rays served 
as the baseline radiographs. 
 
Follow-up examination 
All patients were in individual maintenance care at private offices during the entire study 
period. The clinical and radiological examinations took place 3 and 5 years after insertion of 
the prosthetic reconstructions. All patients were questioned according to a protocol and 
examined clinically and radiologically. 
 
Personal questionnaire 
At the follow-up examinations the influence of the treatment on the health of the peri-implant 
tissues was estimated by the patients who had to fill out an evaluation form in the waiting 
room. This questionnaire consisted either of questions to be answered in written form or of 
visual analog scales (VAS). The condition of the gums and the ability to perform oral hygiene 
were obtained using the VAS. Patients had to make a cross on the scale, which was calibrated 
from “worse” (O%) to “better” (100%). Further there was an evaluation of patient’s 
satisfaction concerning pain, swelling, color of the alveolar mucosa, inflammation, 
uncomfortable sensation and possible unequal sensation on the left and the right side. 
Additionally patients were questioned whether they were in a regular recall interval at the 
dentist and/or at the dental hygienist. Finally, they were asked about their prosthetic 




The clinically evaluated parameters included: (i) full mouth plaque score [FMPS] (Lang et al. 
1986); (ii) full mouth bleeding score [FMBS] (O`Leary et al. 1972); (iii) probing pocket depth 
(PPD) at six sites of each implant and its two adjacent teeth. For the FMPS, the FMBS and 
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the PPD the mesial and distal values have been averaged to one proximal value. The 
evaluation of the prosthetic reconstruction was conducted according to the US Public Health 
Service (USPHS) criteria (Ryge & Cvar 1971). The measured parameters included frame 
fracture, veneer fracture, and occlusal abrasion. 
 
Radiographic evaluation 
For the measurements of the interproximal marginal bone level, radiographs were taken 3 and 
5 years after implant loading (Figures 1 & 2). The radiographic technique consisted of 
periapical radiographs using the parallel technique (Hawe x-ray film holder, Kerrhawe SA, 
Bioggio, Switzerland). Thereafter, the radiographs were digitalized. The marginal bone level 
(ie, the distance from the level of the abutment-implant junction to the fist bone-to-implant 
contact) was measured at the mesial and the distal aspect at a magnification of 5x using an 
image analysis program (Canvas 9, Deneba Systems Inc, USA). The known distance between 
4 implant threads was used for purposes of calibration and determination of the exact 
magnification of the images. Two examiners performed all measurements to the nearest 




The analysis of the radiographic and the clinical data was performed using StatView 5.01 
(Adept Scientific Inc, Acton, USA). The distribution of the data was plotted with box-plots 
and characterized by mean values and standard deviations. Student’s paired t-test was applied 
to detect statistical differences between test and control groups. The level of statistical 






All patients were in a regular recall interval at the dentist or the dental hygienist since the time 
of implant insertion. 
At the 3-year follow-up, all 34 implants in all 11 patients were clinically stable and 
radiologically osseointegrated. At the 5-year follow-up, one patient with 2 implants could not 
be reached for reexamination because of geographical relocation. The remaining 32 implants 
were stable and in function at the 5-year follow-up. Thus, the survival rate of the examined 
implants at 3- and at 5-years was 100 % for the test and the control sites.  
Personal questionnaire 
The evaluation form shows how patients felt three and five years after implant insertion. The 
condition of the gums at the test sites was estimated on the VAS (0%= worse, 100%=better) 
at 69.1 ± 24.2 % (3-years) and 57.5 ± 17.8 % (5-years) and at the control sites at 70.5 ± 23.8 
% (3-years) and 54 ± 22.3 % (5-years). The ability to perform an adequate oral hygiene was 
valued at 76.8 ± 27.2 % (3-years) and 64.5 ± 21.7 % (5-years) at the test sites and at 75.5 ± 
23.8 % (3-years) and 60.5 ± 26.6 % (5-years) at the control sites. One patient complained 
about pain, swelling and inflammation at an implant in the right lower jaw (test implant) at 
the 5-year reexamination.  
Clinical examinations 
Full mouth plaque and bleeding score 
The results of the examinations of the full mouth plaque and bleeding scores are presented in 
Tables 2a & 2b. The patients performed an acceptable oral hygiene. The FMPS for the 3-year 
reexamination was 33% and remained nearly unchanged at the 5-year reexamination  (31%). 
The oral soft tissues showed a tendency to bleed at the 3-year examination (mean FMBS 
31%). A slight improvement was detected at the 5-year examination with a mean FMBS of 
20%. The differences of the FMPS and FMBS values between the 3- to 5-year reexamination 
were not statistically significant for the test and the control group. 
Probing pocket depth 
All results regarding probing pocket depth values are given in Tables 2a & 2b. At the 3-year 
examination, the mean probing depths varied between 2.8mm (buccal sites) and 3.9mm 
 9 
(proximal sites) for the test implants and between 3.1mm (buccal sites) and 4.3mm (proximal 
sites) for the control implants. The corresponding values 5 years after the installation of the 
prosthetic reconstructions ranged from 2.8mm (buccal sites) to 3.4mm (proximal sites) for the 
test implants, and from 2.9mm (buccal sites) to 3.4mm (proximal sites) for the control 
implants (Tables 2a & 2b). The differences of the probing depth values between the 3- and 5-
year examinations were not statistically significant for the test and the control group. 
Patient related prosthetic evaluation 
At the 3-year follow-up, 3 patients reported about crown loosening of 4 screw-retained 
crowns (2 on test, 2 on control implants) during the past 3 years, which could be easily treated 
by retightening of the screws. One patient noticed a chipping of the veneering ceramic at one 
crown at the control site. No crown loosening or chipping of veneering ceramic was reported 
between the 3- and 5-year follow-up.  
Prosthetic examination by operators 
The results of the reexamined prosthetic reconstructions are presented in Table 3a (test sites) 
and Table 3b (control sites) according to the USPHS-criteria. At 3 years, 5 polishable veneer 
fractures were observed, including 2 fixed partial dentures (1 test-, 1 control implant), 2 
splinted crowns (1 test-, 1 control implant), and 1 single crown (control site).  
At 5 years, 7 veneer fractures were detected. Five of these 7 fractures had already been found 
at 3 years. One new fracture (test site, single crown) could be polished; another one was not 
polishable (test site, single crown).  
Radiographic examinations 
Figures 1 & 2 illustrate marginal bone levels over time (from baseline, 3-year examination to 
5-year examination) for both, a test and a control implant. 
The periapical radiographs of all implants at test and control sites did not reveal any signs of 
peri-implant radiolucency at baseline, at the 3- and 5-year follow-up.  
The mean marginal bone levels for all time-points (baseline, 3 years, 5 years) are listed in 
Table 4a (test sites) and Table 4b (control sites). With respect to the marginal bone level, no 
statistically significant differences were observed between test and control sites at baseline, 
the 3-year and the 5-year examinations. Only minimal mean changes (<0.2mm) of the 
marginal bone level occurred at test sites (Table 5a) and control sites (Table 5b) between 
baseline, 3-year and 5-year examinations. The differences between the test and control group 




The present randomized controlled clinical trial revealed excellent long-term outcomes of 
implants placed in bone regenerated by means of GBR techniques with or without the 
addition of rhBMP-2. The 3- and 5-year clinical and radiological examinations demonstrated 
healthy peri-implant tissues with minimal marginal bone loss and only minor prosthetic 
complications. There was no statistically significant difference in any of the examined 
parameters between test and control sites. 
Alveolar ridge augmentation by means of GBR techniques is a well-documented procedure 
characterized by high efficacy and predictability (Chiapasco et al. 2006; Esposito et al. 2006). 
There are sufficient data available in the literature regarding bone augmentation in a one or a 
two-stage procedure using the principle of GBR (Dahlin et al. 1991; Buser et al. 1993; Simion 
et al. 1994; Buser et al. 1996; Zitzmann et al. 2001; Christensen et al. 2003; De Boever & De 
Boever 2005; Blanco et al. 2005). However, the majority of these studies reported only about 
observation periods of less than 5 years. In addition, regarding the use of growth factors in 
dentistry there is very little data available on the long-term outcome of implants placed in 
bone regenerated by means of growth factors (Cochran et al. 1999). Hence, the present study 
was designed to evaluate the 3 and 5 year results of implants placed in bone simultaneously 
regenerated with a xenogenic bone substitute material and a collagen membrane with or 
without the addition of rhBMP-2. 
The results of the present 5-year study showed a survival rate of the reexamined implants at 3- 
and at 5-years of 100% independent of test or control sites. A recent study revealed a survival 
rate of 96.1% after 5 years for implants placed with simultaneous bone augmentation (Blanco 
et al. 2005). A systematic review evaluating implants placed into sites with regenerated bone 
using barrier membranes reported a range of survival rates between 79% and 100% 
(Hämmerle et al. 2002). Within that systematic review one study with a split-mouth design 
reported about implants placed in bone simultaneously regenerated with a graft material 
combined either with a collagen or an e-PTFE membrane (Zitzmann et al. 2001). Using the 
same xenogenic bone grafting material in combination with a resorbable collagen membrane, 
as applied in the present study, a survival rate of 92% after 55-70 months of loading was 
demonstrated. In comparison, a survival rate of 78% was found for the combination of the 
xenogenic bone grafting material with a non-resorbable membrane (Zitzmann et al. 2001). 
These data are based on the treatment of 75 patients with a total of 265 dental implants in 
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which GBR-procedures were applied. A rather small number of included patients might 
explain the higher survival rate of the present study compared to the above-mentioned 
previous studies.  
In the present study, all patients were followed in a regular recall interval at a private dentist 
or a private dental hygienist from the beginning of the implant therapy. The oral hygiene level 
was acceptable with a FMPS of 30% and a FMBS of 31% at the 3-year follow-up and a 
FMPS of 31% and a FMBS of 20% at the 5-year control. Dental literature provides only 
scarce data of long-term studies on GBR-techniques and implant placement evaluating the 
oral hygiene. In a recent prospective long-term clinical study, 13 patients received 16 
implants (De Boever & De Boever 2005). During the follow-up period of 12 to 114 months 
FMPS never reached 20% and also bleeding on probing remained below 20% in all patients. 
In another study plaque was present in 15% of all sites after 60 months (Zitzmann et al. 
2001). The highest frequencies of plaque were found in patients with removable overdentures 
(23.6%), compared to 10.4% for implant supported single tooth crowns and 14.7% for fixed 
partial dentures. A long-term prospective study with 12 implants reported a modified plaque 
index of 0.06 and a modified sulcus bleeding index of 0.5 after 5-year of observation (Buser 
et al.1996). Compared to these studies, the evaluated plaque and bleeding on probing values 
reported in the present study were slightly higher. This might be explained by the fact that the 
patients had to organize their own maintenance program in private offices. 
The evaluated mean PPD varied from 2.8mm to 4.3mm at the 3-year reexamination and form 
2.8mm to 3.4mm after 5 years. The proximal sites showed higher probing depths both at the 
3- and 5-year examination. These results are comparable with those reported in other 
prospective clinical studies. One study reported a mean PPD of 3.44mm (Buser et al. 
1996) and another study found a depth of the peri-implant sulci that rarely exceeded 3mm (De 
Boever & De Boever 2005). 
The personal questionnaire showed a decrease of all secondary effects between the 3- and 5-
year evaluations. In another study, the long-term evaluation of osseointegrated implants at the 
time or after vertical ridge augmentation did not show secondary effects either (Simion et al. 
2001). Very few studies have evaluated patient centered outcomes. Nowadays successful 
implant therapies should not only be presented by osseointegrated and stable implants but also 
by patients satisfaction with the function of the reconstruction and the esthetic appearance.   
Neither the periapical radiographs of the test sites or of the control sites showed any 
continuous peri-implant radiolucency at the 3- and 5-year follow-up examination. In the 
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present study, the mean marginal bone level after 3-years was 1.37mm at the test- and 
1.22mm at the control sites. At the 5-year follow up examination the mean marginal bone 
levels were 1.38mm at the test- and 1.23mm at the control sites. These minimal differences of 
less than 0.2mm between test and control were not statistically significant. The results of this 
study are in agreement with the results reported by other authors. In a 5-year study the 
marginal bone loss levels varied between 1.8mm and 2.2mm when GBR was applied 
(Zitzmann et al. 2001). The mean marginal bone level of implants treated with GBR in 
another study measured 2.03mm after 5-years (Blanco et al. 2005). The authors concluded 
that the application of the principles of GBR using non-resorbable membranes for the 
treatment of dehiscence or fenestration defects render long-term predictable results, both in 
terms of implant survival and maintenance of marginal bone levels. Their therapeutic 
approach would lead to a reduction of the need of more surgeries (such as staged approach) in 
patients with reduced bone volume. 
The minimal changes in mean marginal bone levels between baseline and 5 years (0.03 to 
0.13mm) are in accordance with another clinical study reporting on implants placed in 
regenerated bone (Buser et al. 1996). After 5 years, all 12 implants were osseointegrated and 
showed a mean radiographic bone loss of 0.3mm. In a retrospective multi-center study the 
mean radiographic bone loss over a 74-month period of implants loaded in regenerated bone 
was 0.64mm (Nevins & Mellonig 1998). Compared to these studies the present study revealed 
excellent long-term stability of the marginal bone level. 
BMP-2 is successfully used in general medicine for limited clinical indications, i.e. spine and 
orthopedic surgery. The safety issue in intraoral bone grafting has been recently addressed by 
a review article (Poynton et al. 2002). They reported a transient production of antibodies 
against collagen carriers and against rhBMP-2 in 0.7% of the treated patients. However, the 
clinical relevance of these findings is currently unresolved (Poynton et al. 2002). In 2007, the 
combination of rhBMP-2 and an absorbable collagen sponge (Infuse® Bone Graft, 
Medtronic, Inc., Louisville, USA) was approved by the FDA as an alternative for autogenous 
bone graft for sinus augmentations, and for localized alveolar ridge augmentations for defects 
associated with extraction sockets. This product was the subject of a Premarket Approval 
Application (PMA) for intraoral bone grafting indication and was considered to be safe and 
efficacious for growing bone in the oral cavity. Based on these data, the risks for any immune 
system interactions in the present study appear to be low with respect to rhBMP-2. However, 
no further blood testing was performed in the study patients. In addition, one has to bear in 
mind that several important clinical issues (i.e. release kinetics, dosage, multiple application 
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of bioactive factors) have hardly been address today. Research is needed to further evaluate 
release kinetics and biologic activity of the tested biologic mediator (rhBMP-2) in 
combination with the xenogenic bone substitute and further carrier systems. 
 
CONCLUSIONS 
Based on the data of the present randomized controlled clinical trial, it can be concluded that 
implants placed in bone augmented with a xenogenic bone substitute material and a collagen 
membrane with and without the addition of rhBMP-2 revealed excellent clinical and 
radiological outcomes after 3 and 5 years. However, it must be emphasized that the number of 
patients in the present study was rather small and a clinical documentation of a larger group of 
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Reconstruction  Amount  
 Test Control Total 
Single crowns 3 (13,6%) 5 (22,7%) 8 (36,3%) 
Splinted crowns 2 (9,1%) 2 (9,1%) 4 (18,2%) 
Fixed partial denture 6 (27,3%) 4 (18,2%) 10 (45,5%) 
 
Table 1. Distribution of type of reconstruction. The absolute number of the amount is given 





 Clinical conditions at test implants 
 3-year reexamination 5-year reexamination 
  buccal oral proximal buccal  oral proximal 
Plaque (number of sites) 1 1 13 1 0 7 
BOP (number of site) 1 1 13 1 0 11 
Probing depth (mean) 2.8 mm 3.2 mm 3.9 mm 2.8 mm 2.9 mm 3.4 mm 
   PPD ≤ 3 mm 91% 73% 41% 90% 90% 70% 
   PPD 4-5 mm 9% 27% 50% 10% 10% 23% 
   PPD ≥ 6 mm - - 9% - - 7% 
 




 Clinical conditions at control implants 
 3-year reexamination 5-year reexamination 
  buccal oral proximal buccal  oral proximal 
Plaque (number of sites) 0 1 12 0 0 7 
BOP (number of sites) 1 1 13 0 1 10 
Probing depth (mean) 3.2 mm 3.1 mm 4.3 mm 2.9 mm 3.1 mm 3.4 mm 
   PPD ≤3 mm 82% 82% 25% 90% 80% 75% 
   PPD 4-5 mm 18% 18% 66% 10% 20% 15% 
   PPD ≥6 mm - - 9% - - 10% 
 




 Criteria of the USPHS-index at test sites 
 3-year reexamination 5-year reexamination 
  Alpha Bravo Charlie Delta Alpha Bravo Charlie Delta 
Frame 
fracture 11 (100%) - - - 10 (100%) - - - 
Veneer 
fracture 9 (82%) 2 (18%) - - 7 (64%) 3 (27%) 1 (9%) - 
Occlusal wear 8 (73%) 3 (27%) - - 7 (70%) 3 (30%) - - 
 
Table 3a. Prosthetic reevaluation of the test sites according to the USPHS-criteria. The absolute 




 Criteria of the USPHS-index at control sites 
 3-year reexamination 5-year reexamination 
  Alpha Bravo Charlie Delta Alpha Bravo Charlie Delta 
Frame fracture 11 (100%) - - - 10 (100%) - - - 
Veneer fracture 8 (73%) 3 (27%) - - 8 (73%) 3 (27%) - - 
Occlusal wear 8 (73%) 3 (27%) - - 5 (50%) 5 (50%) - - 
 
Table 3b. Prosthetic reevaluation of the control sites according to the USPHS-criteria. The absolute 









  marginal bone level at test sites (mm) 
 Baseline Baseline 3-year 3-year 5-year  5-year  
 mes dist mes dist mes dist 
Mean 1.33 1.28 1.37 1.36 1.36 1.39 
SD 0.39 0.24 0.33 0.32 0.43 0.43 
Minimum 0.93 0.90 0.91 0.88 0.81 0.89 
Maximum 2.22 1.67 1.96 1.79 2.14 2.26 
 
Table 4a. Mean distances of the first bone to implant contact to the implant abutment junction, 
standard deviations (SD), minimum and maximum values (mm) at the different time points of 
examinations at the test sites. 
 
 
  marginal bone level at control sites (mm) 
 Baseline Baseline 3-year 3-year 5-year  5-year  
  mes dist mes dist mes dist 
Mean 1.20 1.32 1.23 1.21 1.25 1.21 
SD 0.40 0.47 0.38 0.39 0.57 0.46 
Minimum 0.41 0.62 0.35 0.29 0.24 0.78 
Maximum 1.79 1.95 1.78 1.67 2.50 2.34 
 
Table 4b. Mean distances of the first bone to implant contact to the implant abutment junction, 
standard deviations (SD), minimum and maximum values (mm) at the different time points of 




  changes of the marginal bone level at test sites (mm) 
 baseline-3-y baseline-3-y 3-y-5-y  3-y-5-y  baseline-5-y  baseline-5-y  
 mes dist mes dist mes dist 
Mean -0.04 -0.08 -0.03 -0.06 -0.07 -0.11 
SD +0.21 +0.27 +0.19 +0.29 +0.31 +0.31 
Minimum -0.45 -0.58 -0.42 -0.71 -0.53 -0.76 
Maximum +0.27 +0.40 +0.33 +0.38 +0.50 +0.38 
 
Table 5a. Mean changes of marginal bone levels, standard deviations (SD), minimum and maximum 
values (mm) between the different examinations at test sites. Positive values represent a bone gain, 




  changes of the marginal bone level at control sites (mm) 
 baseline-3-y baseline-3-y 3-y-5-y  3-y-5-y  baseline-5-y  baseline-5-y  
 mes dist mes dist mes dist 
Mean -0.02 +0.10 -0.08 -0.04 -0.03 +0.13 
SD +0.33 +0.42 +0.37 +0.32 +0.44 +0.56 
Minimum -0.74 -0.60 -1.05 -0.73 -1.06 -1.02 
Maximum +0.44 +0.62 +0.24 +0.29 +0.50 +0.91 
 
Table 5b. Mean changes of marginal bone levels, standard deviations (SD), minimum and maximum 
values (mm) between the different examinations at control sites. Positive values represent a bone gain, 



















Figure 1. Periapical x-rays showing control implant at position 36 and an additional implant at 
position 35 (not included in study). A. at baseline. B. at 3 years. C. at 5 years. 
 












Figure 2. Periapical x-rays showing test implant at position 47 and an additional implant at position 
46 (not included in study). A. at baseline. B. at 3 years. C. at 5 years. 
 
